Jump to ContentJump to Main Navigation
Intellectual Property Rights, Development, and Catch-UpAn International Comparative Study$
Users without a subscription are not able to see the full content.

Hiroyuki Odagiri, Akira Goto, Atsushi Sunami, and Richard R. Nelson

Print publication date: 2010

Print ISBN-13: 9780199574759

Published to Oxford Scholarship Online: May 2010

DOI: 10.1093/acprof:oso/9780199574759.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2019. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in OSO for personal use (for details see www.oxfordscholarship.com/page/privacy-policy).date: 19 June 2019

Israel's High‐Tech Catch‐Up Process: The Role of IPR and Other Policies

Israel's High‐Tech Catch‐Up Process: The Role of IPR and Other Policies

Chapter:
(p.208) 7 Israel's High‐Tech Catch‐Up Process: The Role of IPR and Other Policies
Source:
Intellectual Property Rights, Development, and Catch-Up
Author(s):

Meir Pugatch

Morris Teubal

Odeda Zlotnick

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780199574759.003.0007

This chapter discusses the experience of Israel. At the time of its independence in 1948, its people came from different parts of the world, providing them with international orientation from the beginning. As a result, many of the businesses targeted foreign markets, mainly USA and Europe, and were more concerned with the intellectual property regime in these foreign countries than Israel's own. Together with public support for innovation and military‐related expenditure, some startup firms, mainly in information technologies, grew and succeeded in IPO (initial public offering) or selling themselves. Another successful case is Teva, now the largest generic drug producer. It benefited from the patent law amendment in 1967, which allowed local firms to copy patented drugs if the patent owners did not market them in Israel. This provision was dropped after TRIPS; however, Teva had accumulated process technologies by then.

Keywords:   Israel, intellectual property, innovation, start‐up, IPO, generic, drug, patent, TRIPS, information technology

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .